Clinical cancer advances 2006: Major research advances in cancer treatment, prevention, and screening - A report from the American Society of Clinical Oncology

Journal of Clinical Oncology

Volumn 25, Issue 1, 2007, Pages 146-162

  Ozols, Robert F ^a   Herbst, Roy S ^a   Colson, Yolonda L ^a   Gralow, Julie ^a   Bonner, James ^a   Curran Jr , Walter J ^a   Eisenberg, Burton L ^a   Ganz, Patricia A ^a   Kramer, Barnett S ^a   Kris, Mark G ^a   Markman, Maurie ^a   Mayer, Robert J ^a   Raghavan, Derek ^a   Reaman, Gregory H ^a   Sawaya, Raymond ^a   Schilsky, Richard L ^a   Schuchter, Lynn M ^a   Sweetenham, John W ^a   Vahdat, Linda T ^a   Winn, Rodger J ^a   Bentsen, Todd ^a   more..

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; ASPARAGINASE MACROGOL; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; LAPATINIB; LENALIDOMIDE; NELARABINE; OXALIPLATIN; PANITUMUMAB; RALOXIFENE; RITUXIMAB; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; THALIDOMIDE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VECTIBIX; VORINOSTAT; WART VIRUS VACCINE; ZOLINDA;

ACNE LIKE RASH; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER RESEARCH; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG ERUPTION; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEPATITIS; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INJECTION SITE REACTION; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKEMIA; LUNG CANCER; LYMPHOMA; MAMMOGRAPHY; MEDICAL RESEARCH; MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OLIGODENDROGLIOMA; OVARY CANCER; PANCREAS CANCER; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SKIN CANCER; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; T CELL LYMPHOMA; TESTIS CANCER; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; WART VIRUS; BLOOD DISEASE; BREAST TUMOR; FEMALE; FEMALE GENITAL TRACT TUMOR; GASTROINTESTINAL TUMOR; HEAD AND NECK TUMOR; LUNG TUMOR; MALE; MORTALITY; NEOPLASM; ONCOLOGY; RESEARCH; SKIN TUMOR; UROGENITAL TRACT TUMOR;

BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; GENITAL NEOPLASMS, FEMALE; HEAD AND NECK NEOPLASMS; HEMATOLOGIC NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MEDICAL ONCOLOGY; NEOPLASMS; RESEARCH; SKIN NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 34547132141     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.7030     Document Type: Article

References (36)

1. Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541, 2006
2. Hochster HS, Weller E, Gascoyne RD, et al: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 Phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Presented at the American Society of Hematology Annual Meeting, December 10-13, 2005, Atlanta, GA
3. Geyer CE, Forster JK, Cameron D, et al: Scientific Special Session: Lapatinib in trastuzumab resistant breast cancer. Presented at the American Society of Clinical Oncology Annual Meeting, June 2-6, 2006, Atlanta, GA
4. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presented at the San Antonio Breast Cancer Symposium, December 8-11, 2005, San Antonio, TX
5. Joensuu H, Kellokumpu-Lehtinen P, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
6. Smith IE: Scientific Special Session: Lapatinib in trastuzumab resistant breast cancer. Presented at the American Society of Clinical Oncology Annual Meeting, June 2-6, 2006, Atlanta, GA
7. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2006
8. Cairncross G, Berkey B, Shaw E, et al: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24:2707-2714, 2006
9. van den Bent MJ, Carpentier A, Brandes A, et al: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol 24:2715-2722, 2006
10. Poplin E, Levy DE, Berlin J, et al: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer. J Clin Oncol 24:18s, 2006 (abstr LBA4004)
11. Heinrich MC, Maki RG, Corless CL, et al: Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol 24, 2006 (abstr 9502)
12. Hudes G, Carducci M, Tomczak P, et al: A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-prognosis patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 24:18s, 2006 (abstr LBA4)
13. Motzer RJ, Hutson TE, Tomczak P, et al: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24:18s, 2006 (abstr LBA3)
14. Bajorin DF, Nichols CR, Margolin KA, et al: Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB. J Clin Oncol 24, 2006 (abstr 4510)
15. National Cancer Institute: Cancer Vaccine Fact Sheet. Available at: http://www.nci.nih.gov/cancertopics/factsheet/cancervaccine.
16. Paavonen J, for the FUTURE II Study Group: Efficacy of a quadrivalent HPV (types 6/11/16/18) L1 virus-like particle (VLP) vaccine against vaginal and vulvar pre-cancerous lesions: A combined analysis. J Clin Oncol 24, 2006 (abstr 5011)
17. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal chemotherapy and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006
18. Bonner JA, Harari PM, Giralt J: Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
19. Posner MR, Hershock D, Le-Lann L, et al: Scientific Special Session: Docetaxel added to induction therapy in head and neck cancer. Presented at the American Society of Clinical Oncology Annual Meeting, June 2-6, 2006, Atlanta, GA
20. Janot F, De Rancourt D, Castaing M, et al: Re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma: A randomized trial from the GETTEC and GORTEC groups. J Clin Oncol 24, 2006 (abstr 5508)
21. Potti A, Mukherjee S, Peterson R, et al: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355:570-580, 2006
22. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006
23. Shepherd FA, Rogdrigues Pereiera J, Cuileanu T, et al: Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. N Engl J Med 353:123-132, 2005
24. Paz-Ares LG, Sanchez JM, García-Velasco A, et al: A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 24, 2006 (abstr 7020)
25. Cappuzzo F, Toschi L, Tricolini R, et al: Clinical and biological effects of gefitinib in EGFR FISH positive/phospho-akt positive or never smoker non-small cell lung cancer (NSCLC): Preliminary results of the ONCOBELL trial. J Clin Oncol 24, 2006 (abstr 7023)
26. Kris MG, Pao W, Zakowski MF, et al: Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy: Preliminary results of the ONCOBELL trial. J Clin Oncol 24, 2006 (abstr 7021)
27. Miller VA, Zakowski MF, Riely GJ, et al: EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. J Clin Oncol 24, 2006 (abstr 7003)
28. Avramis V, Sencer S, Periclou A, et al: A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 99:1986-1994, 2002
29. Food and Drug Administration: FDA Approves Arranon for Rare Leukemia and Lymphoma Drug. FDA Press Release. October 31, 2005
30. Berg S, Blaney SM, Devidas M, et al: Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children's Oncology Group. J Clin Oncol 23:3376-3382, 2005
31. Morton DL, Thompson JF, Cochran AJ, et al: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355:1307-1317, 2006
32. Whiteman DC, Stickley M, Watt P, et al: Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 24:3172-3177, 2006
33. Curtin JA, Fridlyand J, Kagashita T, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147, 2006
34. Fears TR, Guerry D IV, Pfeiffer RM, et al: Identifying individuals at high risk of melanoma: A practical predictor of absolute risk. J Clin Oncol 24:3590-3596, 2006
35. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 295:2727-2741, 2006
36. Bower J, Ganz PA, Desmond KA, et al: Fatigue in long-term breast cancer survivors. Cancer 106:751-758, 2006